Details of the Drug

General Information of Drug (ID: DMM9BJD)

Drug Name

Tisagenlecleucel

Synonyms

Tisagenlecleucel-T

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[2]
Diffuse large B-cell lymphoma	2A81	Phase 3	[2]
Follicular lymphoma	2A80	Phase 2	[2]
Acute myeloid leukaemia	2A60	Application submitted	[3]
------------------------------------------------------------------------------------

ATC Code

L01XL04: Tisagenlecleucel

L01XL: Antineoplastic cell and gene therapy

L01X: OTHER ANTINEOPLASTIC AGENTS

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

CAR T Cell Therapy

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 9.91 days []
Half-life: The concentration or amount of drug in body reduced by one-half in 16.8 days []

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Immunostimulant	[1]
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Immunostimulant	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)